Royalty Pharma (RPRX) Prepaid Assets (2019 - 2026)
Royalty Pharma (RPRX) posted Prepaid Assets of $10.2 million for Q1 2026, up 47.41% sequentially from $6.9 million in Q4 2025, and up 230.01% YoY from $3.1 million in Q1 2025.
Royalty Pharma (RPRX) Prepaid Assets (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Prepaid Assets for 8 years, with the latest figure at $10.2 million in Q1 2026.
- Quarterly Prepaid Assets rose 230.01% year-over-year to $10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (up 230.01% YoY) and the FY2025 annual result came in at $6.9 million, up 64.63% from the prior year.
- Prepaid Assets grew to $10.2 million in Q1 2026 per RPRX's latest filing, from $6.9 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $90.5 million in Q4 2022 and troughed at $2.3 million in Q2 2024.
- A 5-year average of $20.0 million and a median of $5.5 million in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets surged 1265.1% in 2022, then tumbled 92.51% in 2023.
- Over 5 years, Prepaid Assets stood at $90.5 million in 2022, then sank by 80.07% to $18.0 million in 2023, then slumped by 76.79% to $4.2 million in 2024, then soared by 64.63% to $6.9 million in 2025, then jumped by 47.41% to $10.2 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $10.2 million, $6.9 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.66 Mn |
| Mar 31, 2026 | 10.16 Mn |
| Dec 31, 2025 | 6.89 Mn |
| Sep 30, 2025 | 5.52 Mn |
| Jun 30, 2025 | 4.45 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 4.19 Mn |
| Sep 30, 2024 | 4.97 Mn |
| Jun 30, 2024 | 2.29 Mn |
| Mar 31, 2024 | 5.01 Mn |
| Dec 31, 2023 | 18.04 Mn |
| Sep 30, 2023 | 6.78 Mn |
| Jun 30, 2023 | 10.22 Mn |
| Mar 31, 2023 | 4.57 Mn |
| Dec 31, 2022 | 90.52 Mn |
| Sep 30, 2022 | 90.52 Mn |
| Jun 30, 2022 | 67.12 Mn |
| Mar 31, 2022 | 5.39 Mn |
| Dec 31, 2021 | 6.63 Mn |
| Sep 30, 2021 | 8.95 Mn |